Form 4: Acumen Pharma Officer Sells Shares for Tax Obligations
Insider Transaction Report
Acumen Pharmaceuticals' Chief Regulatory Officer, Amy Schacterle, sold 1,097 shares of common stock to cover tax withholding obligations.
Summary
- Amy Schacterle, Chief Regulatory Officer of Acumen Pharmaceuticals, Inc. (ABOS), reported a transaction on January 7, 2026.
- Schacterle sold 1,097 shares of Acumen Pharmaceuticals common stock.
- The shares were sold at a weighted average price of $1.9838 per share, with prices ranging from $1.9550 to $2.0100.
- This sale was an automatic 'sell to cover' transaction to satisfy tax withholding obligations related to the vesting of restricted stock units.
- The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by Schacterle on September 30, 2025.
- Following this transaction, Schacterle beneficially owns 7,703 shares of Acumen Pharmaceuticals common stock directly.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a routine, pre-planned transaction by an insider to cover tax obligations upon RSU vesting, rather than a discretionary sale based on market outlook.
Positives
- The transaction indicates the vesting of restricted stock units, which typically signifies continued employment and achievement of performance milestones by the officer.
Negatives
- The officer's direct beneficial ownership of common stock decreased by 1,097 shares.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This is a routine insider transaction for tax purposes and does not provide specific insights into broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: The transaction represents a minor reduction in an officer's direct holdings, which is a routine event for tax purposes and generally has minimal impact on overall shareholder value or perception.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | Date Reporting Person adopted the Rule 10b5-1 trading plan. |
| 2026-01-07 | Date of the reported transaction (sale of common stock). |
| 2026-01-09 | Date the Form 4 was signed. |
Keywords
Acumen Pharmaceuticals, ABOS, Insider Trading, Form 4, Stock Sale, Sell to Cover, Restricted Stock Units, Tax Obligations, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.